Kite Strikes CAR-T Access & Discount Deal For Tecartus In England
UK Patients Will Be Among The First In The World To Be Offered Access To Tecartus
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
